Recursion Pharmaceuticals Inc., of Salt Lake City, said Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, exercised its option for drug candidates in two rare disease from early results in the companies' October 2017 collaboration using Recursion's AI-fueled expertise.